Skip to main content
Open Access Publications from the University of California

Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI

  • Author(s): Chen, JH
  • Yu, H
  • Lin, M
  • Mehta, RS
  • Su, MY
  • et al.

The purpose of this study was to analyze background parenchymal enhancement (BPE) in the contralateral normal breast of cancer patients during the course of neoadjuvant chemotherapy (NAC).Forty-five subjects were analyzed. Each patient had three MRIs, one baseline (B/L) and two follow-up (F/U) studies. The fibroglandular tissue in the contralateral normal breast was segmented using a computer-assisted algorithm. Based on the segmented fibroglandular tissue, BPE was calculated. BPE measured in baseline (B/L) and follow-up (F/U) MR studies were compared. The baseline BPE was also correlated with age and compared between pre/peri-menopausal (<. 55. years old) and post-menopausal women (≥. 55. years old). The pre-treatment BPE measured in B/L MRI was significantly higher in women <. 55. years old than in women ≥. 55. years old (20.1%. ±. 7.4% vs. 12.1%. ±. 5.1%, p≤. 0.01). A trend of negative correlation between BPE and age was noted (r=0.29). In women <. 55. years old, BPE at F/U-1 (18.8%. ±. 6.9%) was decreased compared to B/L, and was further decreased in F/U-2 (13.3%. ±. 5.7%) which was significant compared to B/L and F/U-1. In women ≥. 55. years old, no significant difference was noted in any paired comparison among B/L, F/U-1 and F/U-2 MRI. A higher baseline BPE was associated with a greater reduction of BPE in F/U-2 MRI (r=0.73). Our study showed that younger women tended to have higher BPE than older women. BPE was significantly decreased in F/U-2 MRI after NAC in women <. 55. years old. The reduction in BPE was most likely due to the ovarian ablation induced by chemotherapeutic agents. © 2013 Elsevier Inc.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Main Content
Current View